{"page":{"totalFilteredElements":75},"studies":[{"active":true,"description":"A Phase 3, Open-label, Multicenter, Randomized&#160;Study of Xaluritamig vs Cabazitaxel or Second&#160;Androgen Receptor-Directed Therapy in&#160;Subjects With Metastatic Castration-Resistant&#160;Prostate Cancer Previously Treated With&#160;Chemotherapy","eudractNumber":"2024-513968-25","id":10039,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-25T10:31:58+02:00","shortTitle":"AMG509 20230005 STEAP-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2","eudractNumber":"2023-507518-28-00","id":11260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT04628026","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-05T11:43:26+02:00","shortTitle":"AMLSG 31-19","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03; D702FC00001)</div>","eudractNumber":"2024-515008-38-00","id":11262,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06627647","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-08T14:04:38+02:00","shortTitle":"ARTEMIDE-Lung03","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)","eudractNumber":"2024-517780-24-00","id":10715,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06868277","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-15T14:04:19+02:00","shortTitle":"ARTEMIDE-Lung04","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Adjuvante Therapie mit Mitotane vs. Mitotane mit Cisplatin und Etoposid nach prim&#228;rer Resektion eines \nlokalisierten Nebennierenrindenkarzinoms mit hohem Rezidivrisiko (ADIUVO-2-Studie) - eine pragmatische, \nrandomisierte, minimalinterventionelle Phase III Studie mit Beobachtungsarm","eudractNumber":"2022-500013-32-01","id":10842,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03583710","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-27T10:25:21+01:00","shortTitle":"Adjuvo-2 / AIO-ENC-0123/ass","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Allogene Stammzelltransplantation im Vergleich zur konventionellen \nTherapie als Salvage-Therapie f&#252;r Patienten mit rezidiviertem / \nprogredientem multiplen Myelom nach einer Erstlinientherapie\n(AlloRelapseMMStudy)","eudractNumber":"2021-001005-67","id":8119,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05675319","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-04-05T10:24:45+02:00","shortTitle":"AlloRelapseMMStudy - CTC201637","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients","eudractNumber":"2025-523990-40-00","id":12095,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-07-07T08:46:17+02:00","shortTitle":"AugMMent/DSMM XXI","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"DAREON&#174;-Lung-1: A Phase III multi-center,\nopen-label, randomised trial of intravenous obrixtamig in combination with\natezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and\netoposide as first-line treatment in patients with extensive-stage small cell\nlung cancer","eudractNumber":"2025-520565-51-00","id":11554,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-07-28T12:21:28+02:00","shortTitle":"BI - 1438-0012 DAREON Lung 1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"<div>Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations</div>","eudractNumber":"2025-521284-12-00","id":11553,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT07195695","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-05-18T15:27:57+02:00","shortTitle":"BI - 1479-0032 - Beamion LUNG 3","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide \n(CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and \nDexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): \nSUCCESSOR-2","eudractNumber":"2022-500861-29","id":10516,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05552976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-11T10:53:21+02:00","shortTitle":"BMS CA057-008 - SUCCESSOR-2","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]}